Invasive Group B Streptococcal Disease in the Elderly, Minnesota, USA, 2003–2007
Neelay J. Kothari

, Craig A. Morin, Anita Glennen, Delois Jackson, Jane Harper, Stephanie J. Schrag, and Ruth Lynfield
Author affiliations: Minnesota Department of Health, St. Paul, Minnesota, USA (N.J. Kothari, C.A. Morin, A. Glennen, J. Harper, R. Lynfield); University of Minnesota, Minneapolis, Minnesota, USA (N.J. Kothari); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (D. Jackson, S.J. Schrag)
Main Article
Table 2
Susceptibility of invasive GBS disease to erythromycin and clindamycin, Minnesota, 2003–2007*
Susceptibility |
No. (%) case-patients
|
p value† |
2003
(N = 133) |
2004
(N = 127) |
2005
(N = 131) |
2006
(N = 143) |
2007
(N = 121) |
Erythromycin susceptible |
95 (71.4) |
86 (67.7) |
87 (66.4) |
90 (62.9) |
71 (58.7) |
0.023 |
Clindamycin susceptible |
114 (85.7) |
105 (82.7) |
108 (82.4) |
116 (81.1) |
92 (76.0) |
0.057 |
Main Article
Page created: September 29, 2010
Page updated: September 29, 2010
Page reviewed: September 29, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.